Comparison of pharmacokinetics and urinary iron excretion of two single doses of deferiprone in β-Thalassemia/hemoglobin e patients

Pharmacology

Volumn 90, Issue 1-2, 2012, Pages 88-94

  Rodrat, Supot ^a   Yamanont, Pavena ^a   Tankanitlert, Jeeranut ^b   Chantraraksri, Udom ^a   Fucharoen, Suthat ^c   Morales, Noppawan Phumala ^a  

^a Mahidol University ^*  (Thailand)

^b Department of Pharmacology   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Deferiprone; Iron overload; Pharmacokinetics; Splenectomy; Thalassemia; Urinary iron excretion

Indexed keywords

DEFERIPRONE; DEFERIPRONE GLUCURONIDE; DRUG METABOLITE; GPO L ONE; HEMOGLOBIN E; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; COMPLEX FORMATION; CORRELATION ANALYSIS; CREATININE CLEARANCE; DISEASE SEVERITY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONJUGATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TRANSFORMATION; FEMALE; HUMAN; IRON CHELATION; IRON EXCRETION; IRON OVERLOAD; MALE; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; URINARY EXCRETION;

ADOLESCENT; ADULT; AREA UNDER CURVE; BETA-THALASSEMIA; FEMALE; GLUCURONIDES; HEMOGLOBIN E; HUMANS; IRON; IRON CHELATING AGENTS; MALE; MIDDLE AGED; PYRIDONES; YOUNG ADULT;

EID: 84863091147     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000339658     Document Type: Article

References (27)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al: Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-1193.
2. Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamoniam K, Skordos G, Si-tarou M, Angastiniotis M: Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 2006;91:1187-1192.
3. Piga A, Roggero S, Salussolia I, Massano D, Serra M, Longo F: Deferiprone. Ann NY Acad Sci 2010;1202:75-78.
4. Kontoghiorghes GJ, Neocleous K, Kolnagou A: Benefits and risks of deferiprone in iron overload in thalassemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003;26:553-584.
5. Roberts D, Brunskill S, Doree C, Williams S, Howard J, Hyde C: Oral deferiprone for iron chelation in people with thalassemia. Cochrane Database Syst Rev 2007;18: CD004839.
6. Traynor K: Deferiprone approved for iron overload. Am J Health Syst Pharm 2011;68: 2106.
7. Barman Balfour JA, Foster RH: Deferiprone: a review of its clinical potential in iron overload in beta-thalassemia major and other transfusion-dependent diseases. Drugs 1999; 58:553-578.
8. Cohen AR, Galanello R, Piga A, DeSanctis V, Tricta F: Safety and effectiveness of long-term therapy with the oral iron chelator de-feriprone. Blood 2003;102:1583-1587.
9. Pootrakul P, Sirankapracha P, Sankote J, Kachinton U, Maungsub W, Sriphen K, Thakernpol K, Atisuk K, Fucharoen S, Chantraluksri U, Shaley O, Hoffbrand V: Clinical trial of deferiprone iron chelation therapy in β-thalassemia/ haemoglobin E patients in Thailand. Br J Haematol 2003;122: 305-310.
10. Wonke B, Wright C, Hoffbrand AY: Combined therapy with deferiprone and deferri-oxamine. Br J Haematol 1998;103:361-364.
11. Viprakasit V, Lee-Lee C, Chong QT, Lin K, Akuhapinant A: Iron chelation therapy in the management of thalassemia: the Asian perspectives. Int J Hematol 2009;90: 435-445.
12. Kattamis A: Combined therapy with defer-oxamine and deferiprone. Ann NY Acad Sci 2005;1054:175-182.
13. Limenta LMG, Jirasomprasert T, Jittang-prasert P, Wilairat P, Yamanont P, Chan-tharaksri U, Fucharoen S, Morales NP: Pharmacokinetics of deferiprone in patients with β-thalassemia: impact of splenectomy and iron status. Clin Pharmacokinet 2011; 50:41-50.
14. Limenta LMG, Jirasomprasert T, Tank-anitlert J, Svasti S, Wilairat P, Chantharaksri U, Fucharoen S, Morales NP: UGT1A6 genotype-related pharmacokinetics of deferi-prone (L1) in healthy volunteers. Br J Clin Pharmacol 2008;65:908-916.
15. International Committee for Standardization in Hematology (ICSH): Recommendation for measurement of serum iron in human blood. Br J Haematol 1978;38: 291-294.
16. Jittangprasert P, Wilairat P, Pootrakul P: Comparison of colorimetry and electrothermal atomic adsorption spectroscopy for the quantification of non-transferrin bound iron in human sera. Southeast Asian J Trop Med Public Health 2004;35:1039-1044.
17. Kontoghiorghes GJ, Chambers S, Hoffbrand AV: Comparative study of iron mobilization from haemosiderin, ferritin and iron (III) precipitates by chelators. Biochem J 1987;241: 87-92.
18. Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L: Pharmacokinetic studies in humans with the oral iron chelators 1,2-dimethyl-3-hydroxypyrid-4- one. Clin Pharmacol Ther 1990;48:255-261.
19. Diav-Citrin O, Atanackvic G, Koren G: An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major. Ther Drug Monit 1999; 21:74-81.
20. Link G, Konji AM, Breuer W, Cabantchik ZI, Hershko C: Exploring the 'iron shuttle' hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001;138: 130-138.
21. Evans P, Kayyali R, Hider RC, Eccleston J, Porter JB: Mechanism for the shuttling of plasma non-transferrin bound iron (NTBI) onto deferoxamine by deferiprone. Transl Res 2010;156:55-67.
22. Ong-ajyooth L, Malasit P, Ong-ajyooth S, Fucharoen S, Pootrakul P, Vasuvattakul S, Siritanaratkul N, Nilwarangkur S: Renal function in adult beta-thalassemia/HbE disease. Nephron 1998;78:156-161.
23. Quinn CT, Johnson VL, Kim HY, Trachten-berg F, Vogiatzi MG, Kwiatkowski JL, Neufeld EJ, Fung E, Oliveri N, Kirby M, Giardina PJ: Renal dysfunction in patients with thalassemia. Br J Haematol 2011;153: 111-117.
24. Al-Refaie FN, Sheppard LN, Nortey P, Wonke B, Hoffbrand AV: Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol 1995;89:403-408.
25. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, Nortey P: Long term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). 1. Iron chelation and metabolic studies. Br J Haematol 1990;76:295-300.
26. Collins AF, Fassos FF, Stobie S, Lewis N, Shaw D, Fry M, Templeton DM, McClelland RA, Koren G, Olivieri NF: Iron balance and dose response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded patients with sickle cell disease. Blood 1994;83:2329-2333.
27. Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, St Louis P, Freedman MH, McClelland RA, Templeton DM: Comparison of oral iron chelator L1 and deferriox-amine in iron-loaded patients. Lancet 1990; 336:1275-1279.